Diligence memo · auto-generated · as of July 2, 2026
Vdyne, Inc.
Vdyne, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Vdyne, Inc. operates in Biotechnology, based in MAPLE GROVE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vdyne, Inc. has raised $33M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $13M on 2020-08-14.
Most recent recorded round closed around 2020-12-09.
Valuation (modeled)modeled
Provath models Vdyne, Inc. at approximately $234M (range $8.7M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.29× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era. Within the normal band (129% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 5.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 76% of Biotechnology peers (4293 compared).
Modeled value ranks above 74% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.